Pharma & Biotech Global Week in Review 4 Nov 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

US: District Court S D New York denies motions to dismiss in gene patent case: Association for Molecular Pathology v USPTO (Inventive Step) (Patent Docs) (Patent Baristas) (Ars Technica) (The IP Factor) (Patently-O) (IP Watch)

Plavix (Clopidogrel) – US: Supreme Court rejects Plavix patent challenge by Apotex (GenericsWeb) (IP World)

US: Mayo asks Supreme Court to review another patentable subject matter case: Mayo v Prometheus (Inventive Step) (Patently-O)

Ecuador grants obligatory patent licenses (IP tango) (IP tango) (IP tango)

 
General

Medicines access again captures attention at WTO as progress urged in round (IP Watch)

Open source and biotechnology: Whither or whether idea? (IP finance)

Brazil: BPTO v ANVISA (Health National Surveillance Agency): Pharmaceutical patents in Brazil (IP tango)

Canada finds patents no help for poorest in need of medicine (IP Watch)

Ecuador grants obligatory patent licenses (IP tango) (IP tango) (IP tango)

India: Glenmark Pharmaceuticals and Suven Life Sciences: The new face of the innovating ‘Indian’ pharma industry? (Spicy IP)

India approaches WTO as yet another seizure takes place (Spicy IP)

UK: IPO issues SPC guide (The SPC Blog)

US: Follow-on biologics data exclusivity debate scorecard (Part 1 – Patent Docs) (Part II – Patent Docs) (Part III – Patent Docs)

US: 12 Senators write in support of 12-year data exclusivity period (Patent Docs)

US: Affordable Health Care for America Act introduced in House; includes biosimilar licensure pathway (FDA Law Blog) (Patent Docs)

US: Mayo asks Supreme Court to review another patentable subject matter case: Mayo v Prometheus (Inventive Step) (Patently-O)

US: Changing winds for gene patenting in the US? Stakeholders react to draft report (IP Watch)

US: District Court S D New York denies motions to dismiss in gene patent case: Association for Molecular Pathology v USPTO (Inventive Step) (Patent Docs) (Patent Baristas) (Ars Technica) (The IP Factor) (Patently-O) (IP Watch)

 
Products

Ceclor (Cefaclor) – Canada: Eli Lilly successful in patent infringement action against Apotex (Pharmacapsules @ Gowlings)

Oxytrol (Oxybutynin) – US: Watson and Barr settle patent litigation (SmartBrief)

Plavix (Clopidogrel) – US: Supreme Court rejects Plavix patent challenge by Apotex (GenericsWeb) (IP World)

Razadyne (Galanthamine) – US: CAFC: Patent enablement requires more than a guess: In re ‘318 Patent Infringement Litigation (The IP Law Blog)

Tricor (Fenofibrate) – US: Impax Laboratories challenges Abbott’s patent relating to Tricor (SmartBrief)

Zyprexa (Olanzapine) – Canada: Federal Court decides Apotex precluded from pursuing current NOA which is null and void: Eli Lilly Canada v Apotex (Pharmacapsules @ Gowlings)

Zyprexa (Olanzapine) – Canada: Federal Court finds patent invalidity: Eli Lilly v Novopharm (Pharmacapsules @ Gowlings)

Zyprexa (Olanzapine) – Germany: Xth Senate of Bundesgerichtshof allows appeal against decision rendering Eli Lilly’s patent for pharmaceutical compound Olanzapine null and void: Eli Lilly & Co v Egis Gyogysergya Rt (JIPLP)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: